

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 18

September 29th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- COA Site of Care Cost Analysis
- ASCO Comments on MPFS
- ANCO's 4Q2017 Hematologic Malignancies Updates
- NCCN Categories of Preference

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on October 20th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The ANCO FAX News has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

A new study entitled *The Value of Community Oncology: Site of Care Cost Analysis* conducted by *Florida Cancer Specialists & Research Institute* and *Excenda* and released by the *Community Oncology Alliance* (COA) finds that the total cost of care for cancer patients receiving chemotherapy delivered in the hospital outpatient setting is nearly 60% more expensive than the same treatment delivered in independent, community oncology practices. The findings were consistent across all cancers. The analysis also found that rates of emergency department visits by cancer patients following chemotherapy were higher in the hospital outpatient setting than the community practices. The higher costs of cancer care in the hospital outpatient setting appear to be primarily driven by the increased cost of chemotherapy and physician visits. Read the full study at www.communityoncology.org/wp-content/uploads/2017/09/Site-of-Care-Cost-Analysis-White-Paper_9.25.17.pdf.

Bobbi Buell's recent *E-Reimbursement News* (9/18/17) discusses new ICD-10-CM codes effective on October 1st and is available at www.anco-online.org/EReimbursementNews09182017.pdf.

CMS has released its proposed CY2018 *Physician Fee Schedule* (PFS) and *Outpatient Prospective Payment System* (OPPS) rules. Read the proposed rule at [payment-and-ambulatory-surgical-center-payment; read the fact sheet at \[www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html\]\(http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html\). Major changes include a reduction in payments to hospitals participating in 340B under OPPS. Overall, physician payment rates will increase by .31% in CY2018 compared to CY2017, including an estimated 1% increase for radiation oncology. Read Bobbi Buell's summary of the proposed rule at \[www.anco-online.org/BBMPFS2018Analysis.pdf\]\(http://www.anco-online.org/BBMPFS2018Analysis.pdf\). Read ASCO's comments on the proposed rules at \[www.asco.org/advocacy-policy/asco-in-action/cms-urged-ensure-fair-adequate-medicare-reimbursement-oncologists\]\(http://www.asco.org/advocacy-policy/asco-in-action/cms-urged-ensure-fair-adequate-medicare-reimbursement-oncologists\); read ASH's comments on the proposed rules at \[www.hematology.org/Advocacy/Testimony.aspx/\]\(http://www.hematology.org/Advocacy/Testimony.aspx/\); read ACCC's comments on the proposed OPPS and PFS rules at \[www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-OPPS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=5oSB4\]\(http://www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-OPPS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=5oSB4\) and \[www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-PFS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=6oSB4\]\(http://www.accc-cancer.org/advocacy/pdf/ACCC-CY-2018-PFS-Proposed-Rule-Comment-Letter.pdf?_zs=bhddd1&_zl=6oSB4\), respectively.](http://www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-</p>
</div>
<div data-bbox=)

The Medicare Quality Payment Program (QPP), established by the *Medicare Access and CHIP Reauthorization Act* (MACRA), began on January 1st. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information. In addition, CMS is now accepting hardship exceptions from the QPP for the 2017 reporting year based on insufficient internet connectivity, extreme and uncontrollable circumstances, and lack of control over the availability of certified EHR technology. Learn more at qpp.cms.gov/about/hardship-exception.

CMS has issued a proposed rule that would make changes in the second year of the QPP. The proposed rule “aims to simplify the program, especially for small, independent, and rural practices.” Read the CMS fact sheet at qpp.cms.gov/docs/QPP_Proposed_Rule_for_QPP_Year_2.pdf; and, read Bobbi Buell’s analysis at www.anco-online.org/BBMIPS2018.pdf. ASCO submitted comments to CMS on the proposed rule arguing that its data show that the median financial penalty for oncology practices under the proposal would range from 14-23%, well beyond the CMS-envisioned 4% penalty. ASCO urged CMS to refrain from implementing such a policy at any point in time. In addition, ASCO urged CMS to implement multiple oncology-focused APMs, including its own PCOP model. Read ASCO’s comments at www.asco.org/sites/new-www.asco.org/files/content-files/QPP-2018-Proposed-Rule-Comments.pdf; read ASH’s comments at www.hematology.org/Advocacy/Testimony.aspx; read ACCC’s comments at accancer.org/ACCCbuzz/acc-comments-to-cms-on-quality-payment-program-proposed-rule/?utm_source=ACCCConnect&utm_medium=email&utm_campaign=ACCCConnect091317&_z_s=bhddd1&_zl=8oSB4.

CMS invites representatives from organizations of all sizes to assess current and future functionality of the *Quality Payment Program* website (qpp.cms.gov) as well as make recommendations for improvements. If interested, then e-mail partnership@cms.hhs.gov to participate in a one-on-one feedback session.

Unsure of your MIPS participation status? Clinicians can now use an interactive tool on the CMS *Quality Payment Program* website to determine if they should participate in MIPS. Visit qpp.cms.gov > Check Now, enter your NPI and information will then be provided on whether or not you should participate in MIPS in 2017 and where to find resources.

CMS is encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP. To subscribe to the QPP listserv, go to qpp.cms.gov and select “Subscribe to Email Updates” at the bottom of the page.

ASCO is pleased to announce that its *Quality Oncology Practice Initiative (QOPI) Qualified Clinical Data Registry (QCDR)* is now available for CMS MIPS reporting effective July 1st. By using the QOPI QCDR for MIPS reporting, practices will be able to report on one measure for one patient in 2017 to avoid cuts to Medicare reimbursements in 2019. Express your interest in participating in the QOPI QCDR by e-mailing qopi@asoc.org. Once registration is officially open, practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting. Registration closes October 1st.

ASCO’s series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. **ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status** at www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status. For more information and access to ASCO’s revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra. ASH’s updated MACRA webpage is at www.hematology.org/Clinicians/7427.aspx. **ASH members can now sign up to report data for the Medicare MIPS through *Healthmonix’s* MIPSPRO, a 2017 Qualified MIPS Registry.** Learn more at healthmonix.com/mips-pro/.

The *American Medical Association (AMA)* has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a*

Medicare payment penalty with basic reporting.

The video and other AMA resources are available at www.ama-assn.org/qpp-reporting. CMA's **Center for Economic Services (CES)** has published an update to its MACRA preparation checklist entitled *MACRA: What Should I Do Now to Prepare?* available at www.cmanet.org/macra. Physicians in practices with 15 or fewer can receive free assistance to prepare and participate in the QPP through the **California Health Information Partnership & Services Organization (CalHIPSO)**. Contact CalHIPSO at www.hsag.com/calhipso.

CMA, MOASC, and State Legislative & Regulatory Issues

The **California Medical Association (CMA)** is receiving reports from physician offices that **Anthem Blue Cross** is not paying the "interim payment" as required under the recently effective law (AB72) limiting out-of-network billing for covered, non-emergent services performed at an in-network facility. If your practice has received an incorrect payment from **Anthem** or any other payor related to the new law, CMA wants to hear from you at (888) 401-5911 or via e-mail at economicservices@cmanet.org. For more information about AB72, visit www.cmanet.org/ab-72.

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the California Medical Association (CMA)**. While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you. The CMA's Center for Economic Services (CES) has a team of reimbursement specialists**

available to assist ANCO's CMA members experiencing payment problems with third-party payers. For membership, please call (916) 551-2042; for reimbursement assistance, please call CMA's *Reimbursement Helpline* at (888) 401-5911.

CMA's **Center for Economic Services** has published updated payor profiles on each of the major payors in California at www.cmanet.org/resources/reimbursement-assistance/payor-profiles/.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's **Center for Economic Services** that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) **Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the **Noridian/JEMAC** website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Transition to New Medicare Numbers and Cards; Chronic Care Management: Connected Care Videos; Quality Payment Program: Hardship Exception Application for 2017 Transition Year Available; Medicare Clinical Laboratory Fee Schedule: Preliminary CY2018 Payment Rates; 2016 PQRS Feedback Reports and Annual QRURs Updates; Quality Payment Program: New Resources Available; Quality Payment Program: View Recordings of Recent Webinars;

MIPS Eligible Measure Applicability:
 New Resources Available
Events—2016 Annual QRURs Webcast-
 October 19
Publications—Transition to New
 Medicare Numbers and Cards Fact Sheet-
 New; SNF Consolidated Billing Web-
 Based Training Course-Reminder;
 Remittance Advance Resources and FAQs
 Fact Sheet-Reminder

- Flow Cytometry LCD-R8
- Nerve Blockade for Treatment of
 Chronic Pain and Neuropathy LCD-R10
- Diagnostic and Therapeutic
 Colonoscopy LCD-R9 and R10
- Update Editing of Always Therapy
 Services-MCS-Revised CR10176
- October Webinars-Register Now

Noridian/JEMAC's Electronic Data
 Interchange Support Services (EDISS) invites
 you to subscribe to its e-mail distribution list
 to receive current information at
www.edissweb.com/cgp/news/index.html.

EDUCATION

*[Editor's Note: ANCO organizes clinical and professional
 education meetings throughout the year and throughout Northern
 California.]*

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic
 Malignancies Updates* in 2017. The third and
 final *Update* takes place on November 4th at the
San Francisco Hyatt Regency with Mehrdad Abedi,
 M.D., *University of California, Davis*, Sandy W.
 Wong, M.D., *University of California, San
 Francisco*, and Leena T. Rahmat, M.D.,
University of California, San Francisco. The latest
 research on novel treatment modalities for
 hematologic malignancies, myeloma, and
 amyloidosis, along with case studies for these
 diagnoses will be presented. These updates are
 supported by *Janssen Biotech, Merck, Pfizer*

Oncology, and Pharmacoclytics. Download the
 meeting announcement at www.anco-online.org/4Q2017HemeMaligUpdate.pdf.

SAVE THE DATE 18th Multidisciplinary Management of Cancers: A Case-based Approach

The *18th Multidisciplinary Management of
 Cancers: A Case-based Approach* returns to the
Silverado Resort and Spa in Napa on March 16-
 18th. The meeting is sponsored by the *Association
 of Northern California Oncologists, Stanford
 Cancer Institute, UC Davis Comprehensive Cancer
 Center, and the UCSF Helen Diller Family
 Comprehensive Cancer Center*. Go to
www.multicancers.org to register your interest in
 receiving registration and housing information
 when it becomes available in the Fall.

Additional Education Meetings

October 2nd

Treatment Update on Liver Cancer
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

October 4th

*What's New in the Treatment of Waldenstrom's
 Macroglobulinemia (WM)*
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

October 5th

*Progress in the Treatment of Indolent Non-Hodgkin
 Lymphoma*
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

October 6th

Update on Soft Tissue Sarcoma
 CancerCare Connect Education Workshop
 (www.cancercare.org/connect_workshops)

October 6-7th

12th Annual Congress: Hematologic Malignancies
 NCCN
 San Francisco
 ([www.nccn.org/professionals/meetings/
 hematological/default.aspx](http://www.nccn.org/professionals/meetings/hematological/default.aspx))

October 18-20th
34th National Oncology Conference
ACCC
Nashville
(www.accc-cancer.org/meetings/NOC2017.asp)

October 19th
Living with Metastatic Breast Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 27-28th
Palliative and Supportive Care in Oncology Symposium
ASCO
San Diego
(www.pallonc.org)

November 1st
Update on the Treatment of Pancreatic Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 11th
Best of WCLC 2017-San Francisco
International Association for the Study of Lung Cancer
San Francisco
(www.eventbrite.com/e/best-of-the-18th-wclc-san-francisco-tickets-37865231928)

November 11th
2nd Annual Symposium on Integrating Immune Therapies & Targeted Therapies into Standards of Care for Solid and Hematologic Malignancies
Global Resource for Advancing Cancer Education
San Francisco

November 14th
Update on Mantle Cell Lymphoma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

November 15th
Mind Body Techniques to Cope with the Stresses of Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Annual Election

Four seats on the ANCO *Board of Directors* are up for election in 2017. ANCO seeks nominations for candidates for these seats. This year's election will be conducted via mail ballot in December. Candidates with the top four vote totals will serve for three years (i.e., from 2018-2020, inclusive). Nominate an ANCO member (including yourself) to stand for election to the *Board* via e-mail/FAX to the ANCO office at execdir@anco-online.org/(415) 472-3961.

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The next regularly scheduled ANCO *Board of Directors* meeting is scheduled for October 17th. Please call José Luis González, ANCO Executive Director, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

ANCO is pleased to announce that several members—Daniel Mirda, M.D., ANCO President, Bradley Ekstrand, M.D., ANCO Vice President, Minggui Pan, M.D., ANCO Board Member, Thomas Marsland, M.D., Piyush Srivastava, M.D., and Harvey Bichkoff, M.P.H.—have been named ASCO *Advocacy Champions*. *Advocacy Champions* are ASCO volunteers who have been exceptionally active in ASCO's advocacy activities throughout the year meeting with *Federal* lawmakers and agencies, sending personalized letters to *Members* of

Congress through ASCO's ACT Network, engaging with *State* lawmakers on policy priorities at the *State* level, and holding site visits during *Congressional* recesses. ANCO thanks these members for their efforts!

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, and *Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

UC San Francisco informs ANCO members that *Benioff Children's Hospital San Francisco* is one of the few centers in the country that is certified to provide CAR-T cell therapy for pediatric and young adult patients (less than 25 years of age) who have B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. To refer a patient to our pediatric or adult cancer programs, call UCSF Pediatric Immunotherapy Program (415) 476-3831,

UCSF Helen Diller Family Comprehensive Cancer Center (415) 353-2051, or UCSF HDFCCC Clinical Trials (877) 827-3222.

The *UCSF Stephen and Nancy Grand Multiple Myeloma Initiative* invites ANCO members to join them at their annual retreat on October 2nd on the UCSF Mission Bay Campus. For more information, contact Cammie Edwards, *Program Director, Grant MMTI* at cammie.edwards@ucsf.edu

The *Stanford Cancer Center's MDS Center* is co-sponsoring a the MDS Foundation's Educational Patient-Caregiver Forum on Saturday, October 28th. The Forum takes place at 875 Blake Wilbur Drive, Room 2103, Stanford, CA 94305 from 9:30AM through 2PM.

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheragnostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Puma Biotechnology • Sandoz Biopharmaceuticals
Sanofi Genzyme • Seattle Genetics*

*Taiho Oncology • Takeda Oncology • Tesaro
TEVA Oncology*

We especially wish to thank and welcome *Agendia, bioTheragnostics, EMD Serono, Kite Pharmaceuticals, Pfizer US Biosimilars, and Puma Biotechnology* as new Corporate Members for 2017. *Dendreon, Genoptix Medical Laboratory, GenPath Oncology, Infinity Pharmaceuticals, Ipsen Biopharmaceuticals, Medivation, Merrimack Pharmaceuticals, and Prometheus Laboratories* did not renew their memberships for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Bristol-Myers Squibb Oncology informs ANCO that the *United States Food and Drug Administration* has approved Opdivo for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.

Ipsen Biopharmaceuticals informs ANCO that the *United States Food and Drug Administration* has approved a supplemental indication for Somatuline Depot for the treatment of carcinoid syndrome.

Merck informs ANCO that the *United States Food and Drug Administration* has approved Keytruda for patients with recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test. Patients must have had disease progression on or after two or more prior systemic therapies, including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapy.

Sanofi Genzyme informs ANCO that the *United States Food and Drug Administration* has approved a lower dose of Jevtana (20mg/m² every 3 weeks) in combination with prednisone for the treatment

of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Clinical Trial News

***UC San Francisco* brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:**

- A Phase Ib and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 or Sunitinib in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate/KIT Directed Tyrosine Kinase Inhibitor (TKI) Therapy (CC#174522). Contact: Samantha Maisel, (415) 502-3310, samantha.maisel@ucsf.edu
- A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma. (CC#16451) Contact: Trang Nguyen, (415) 353-9544; trangx.nguyen@ucsf.edu
- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer; CC#175612). Contact: Shohei Burns, (415) 514-6258; shohei.burns@ucsf.edu
- Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial; CC#174513). Contact: Trang Nguyen, (415) 353-9544; trangx.nguyen@ucsf.edu
- A Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer (CC#174517). Contact: Julia Whitman, (415) 353-7683; julia.whitman@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to apps.asco.org/oncology-practice-central/survey.

The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date and will continue to grow as more guidelines and tools are added. Download the app at www.asco.org/guidelines or www.asco.org/apps.

ASCO's Clinical Affairs Department provides services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO is launching its new Practice Engagement Program to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system. Building on an array of resources developed to help practices remain viable and thrive during this turbulent period, the new *Practice Engagement Team* will help participating practices

learn more about the specific ASCO services and programs that can best support their needs. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program-connects-practices-specific-resources.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

The September 2017 issue of ASCO's *Journal of Oncology Practice (JOP)* is available online and features articles entitled *Responding to Patient Requests for Hastened Death: Physician Aid in Dying and the Clinical Oncologist* and other articles, editorials, and op-eds on this topic. Visit jop.ascopubs.org for more information.

ASCO and Innovative Oncology Business Solutions (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

ASCO's Cancer.Net is ASCO's patient education website (www.cancer.net) that provides timely, comprehensive, oncologist-approved information to people living with cancer, their caregivers, and families to help them make informed health care decisions.

Visit the **2017 ASH Meeting on Hematologic Malignancies Webcast** for more than 11 hours of exclusive content at ashondemand.org/Meeting/117851630.

ACCC's 2017 Patient Assistance and Reimbursement Guide (updated September 2017) is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/PatientAssistanceGuide.asp? to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, tablet, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org. **ASH also has a webpage** (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs. And, at NCCN's Reimbursement Resource Room (www.nccn.org/reimbursement_resource_room/default.asp) you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you. Finally, *assistPoint* is your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria*, and/or

Radiation Therapy Compendium for B-cell lymphomas (V5.2018), basal cell skin cancer (V1.2018), Burkitt lymphoma (V4.2017), central nervous system cancers (V1.2018), dermatofibrosarcoma protuberans (V1.2018), esophageal and esophagogastric cancer (V3.2017), gastric cancer (V4.2017), hairy cell leukemia (V2.2018), Merkel cell carcinoma (V1.2018), multiple myeloma (V1.2018), non-melanoma skin cancers (V1.2018), prostate cancer early detection (V2.2017), small cell lung cancer (V1.2018), squamous cell skin cancer (V1.2018). Go to www.nccn.org for more information.

NCCN has announced that it has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics within the NCCN Guidelines for multiple myeloma. Additional cancer types will be forthcoming. The Categories of Preference are preferred intervention, other recommended interventions, and useful in certain circumstances. Learn more about Categories of Preference at www.nccn.org/images/guidelines/PDF/NCCN_Categories_of_Preference_FAQ.pdf.